BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 10875452)

  • 1. The impact of race on freedom from prostate-specific antigen failure in prostate cancer patients treated with definitive radiation therapy.
    Young CD; Lewis P; Weinberg V; Lee TT; Coleman CW; Roach M
    Semin Urol Oncol; 2000 May; 18(2):121-6. PubMed ID: 10875452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: radiation oncology report of the Department of Defense Center for Prostate Disease Research.
    Johnstone PA; Kane CJ; Sun L; Wu H; Moul JW; McLeod DG; Martin DD; Kusuda L; Lance R; Douglas R; Donahue T; Beat MG; Foley J; Baldwin D; Soderdahl D; Do J; Amling CL
    Radiology; 2002 Nov; 225(2):420-6. PubMed ID: 12409575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer in African-American men: outcome following radiation therapy with or without adjuvant androgen ablation.
    Zagars GK; Pollack A; Pettaway CA
    Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):517-23. PubMed ID: 9806509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of race on biochemical disease-free survival in early-stage prostate cancer patients treated with surgery or radiation therapy.
    Hart KB; Wood DP; Tekyi-Mensah S; Porter AT; Pontes JE; Forman JD
    Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1235-8. PubMed ID: 10613318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate.
    Winkfield KM; Chen MH; Dosoretz DE; Salenius SA; Katin M; Ross R; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e345-50. PubMed ID: 21514066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
    Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3D conformal radiation therapy (3DCRT) for high grade prostate cancer: a multi-institutional review.
    Fiveash JB; Hanks G; Roach M; Wang S; Vigneault E; McLaughlin PW; Sandler HM
    Int J Radiat Oncol Biol Phys; 2000 May; 47(2):335-42. PubMed ID: 10802357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rates of biochemical remission remain higher in black men compared to white men after radical prostatectomy despite similar trends in prostate specific antigen induced stage migration.
    Wood HM; Reuther AM; Gilligan TD; Kupelian PA; Modlin CS; Klein EA
    J Urol; 2007 Oct; 178(4 Pt 1):1271-6. PubMed ID: 17698101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of race on prostate-specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate.
    Cross CK; Shultz D; Malkowicz SB; Huang WC; Whittington R; Tomaszewski JE; Renshaw AA; Richie JP; D'Amico AV
    J Clin Oncol; 2002 Jun; 20(12):2863-8. PubMed ID: 12065563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative influence of Gleason score and pretreatment PSA in predicting survival following brachytherapy for prostate cancer.
    Beyer DC; Thomas T; Hilbe J; Swenson V
    Brachytherapy; 2003; 2(2):77-84. PubMed ID: 15062144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.
    Moul JW; Sesterhenn IA; Connelly RR; Douglas T; Srivastava S; Mostofi FK; McLeod DG
    JAMA; 1995 Oct; 274(16):1277-81. PubMed ID: 7563532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era.
    Kuban DA; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Sandler HM; Shipley WU; Zelefsky MJ; Zietman AL
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):915-28. PubMed ID: 14575822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era.
    Kupelian PA; Buchsbaum JC; Patel C; Elshaikh M; Reddy CA; Zippe C; Klein EA
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):704-11. PubMed ID: 11849793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer stage shift has eliminated the gap in disease-free survival in black and white American men after radical prostatectomy.
    Bianco FJ; Wood DP; Grignon DJ; Sakr WA; Pontes JE; Powell IJ
    J Urol; 2002 Aug; 168(2):479-82. PubMed ID: 12131292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Racial differences in serum prostate-specific antigen (PSA) doubling time, histopathological variables and long-term PSA recurrence between African-American and white American men undergoing radical prostatectomy for clinically localized prostate cancer.
    Tewari A; Horninger W; Badani KK; Hasan M; Coon S; Crawford ED; Gamito EJ; Wei J; Taub D; Montie J; Porter C; Divine GW; Bartsch G; Menon M
    BJU Int; 2005 Jul; 96(1):29-33. PubMed ID: 15963115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of race on biochemical control in patients with localized prostate cancer treated with permanent brachytherapy: multivariate and matched-pair analyses.
    Lee LN; Barnswell C; Torre T; Fearn P; Kattan M; Potters L
    Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):282-9. PubMed ID: 12023131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association between presentation PSA and race in two sequential time periods in prostate cancer patients seen at a university hospital and its community affiliates.
    Pan CC; Lee JS; Chan JL; Sandler HM; Underwood W; McLaughlin PW
    Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1292-6. PubMed ID: 14630264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer biochemical recurrence stage for stage is more frequent among African-American than white men with locally advanced but not organ-confined disease.
    Powell IJ; Banerjee M; Novallo M; Sakr W; Grignon D; Wood DP; Pontes JE
    Urology; 2000 Feb; 55(2):246-51. PubMed ID: 10688088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era.
    Pollack A; Smith LG; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):507-12. PubMed ID: 10974469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.